CAMBRIDGE, England--(BUSINESS WIRE)--Adrestia Therapeutics, a leader in synthetic rescue therapies for genetic diseases, today announced that it was acquired in June of 2023 by Insmed Incorporated ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results